# Patrick Roberts

> Patrick Roberts, PharmD, PhD, is the chief executive officer and co-founder of Incyclix Bio, a Research Triangle Park biotechnology company developing selective cyclin-dependent kinase inhibitors. A pharmacist-scientist trained at the University of Kentucky and the University of North Carolina at Chapel Hill, he spent more than a decade at G1 Therapeutics, helped guide trilaciclib from discovery toward patients, and now leads the clinical development of Incyclix's CDK2 inhibitor INX-315.

- **Role:** Chief Executive Officer and Co-Founder at Incyclix Bio
- **Organizations:** Incyclix Bio, G1 Therapeutics, University of North Carolina at Chapel Hill, EMD Pharmaceuticals
- **Education:** PharmD, University of Kentucky College of Pharmacy, PhD in Pharmaceutical Sciences, University of North Carolina at Chapel Hill
- **Known for:** Helped G1 Therapeutics grow from an incubated startup to a publicly traded company with three compounds in clinical development., Contributed early scientific work that supported the myelopreservation concept., Served as project leader guiding trilaciclib from discovery toward patients and participated in the program's NDA-stage regulatory work.

## Career timeline

- **2005-2007** — Worked as a consultant at EMD Pharmaceuticals.
- **2007-2012** — Conducted postdoctoral research at the University of North Carolina at Chapel Hill.
- **2009-2020** — Held scientific and translational-medicine roles at G1 Therapeutics, ultimately leading translational medicine.
- **2020** — Co-founded Incyclix Bio and became chief executive officer.
- **2023** — Incyclix received FDA clearance for the IND application for INX-315 and began a Phase 1/2 study.
- **2024** — Co-authored a Cancer Discovery paper describing INX-315 and presented interim clinical data with collaborators at the San Antonio Breast Cancer Symposium.
- **2025** — Incyclix received FDA Fast Track designation for INX-315 in a defined ovarian-cancer setting, published biomarker research, and raised an $11.25 million Series B extension.
- **2026** — Incyclix raised an additional $5 million from Hatteras Venture Partners to advance the INX-315 Phase 1/2 trial.

## Achievements

- Helped G1 Therapeutics grow from an incubated startup to a publicly traded company with three compounds in clinical development.
- Contributed early scientific work that supported the myelopreservation concept.
- Served as project leader guiding trilaciclib from discovery toward patients and participated in the program's NDA-stage regulatory work.
- Co-founded Incyclix Bio in 2020 and advanced INX-315 into a multinational Phase 1/2 clinical trial.
- Co-authored peer-reviewed research on selective CDK2 inhibition in Cancer Discovery and Nature Communications.
- Led Incyclix through FDA Fast Track designation for INX-315 and multiple Series B financing extensions.

## Latest updates

- **2026-04** — Incyclix Bio raised an additional $5 million in Series B financing from Hatteras Venture Partners to support its Phase 1/2 INX-315 trial.
- **2026-03** — Roberts discussed Incyclix's relationship-driven approach to identifying and working with key opinion leaders in a Clinical Leader interview.
- **2025-12** — Incyclix appointed oncology drug developer Kimberly Blackwell to its board as an independent director.
- **2025-09** — Incyclix was named one of Fierce Biotech's 2025 Fierce 15 companies.
- **2025-08** — Incyclix secured an $11.25 million Series B extension to advance the ongoing INX-315 clinical trial.

## Links

- Website: https://incyclixbio.com
- LinkedIn: https://www.linkedin.com/in/pjroberts77

---

Profile page: https://yespress.io/patrick-roberts
Published by YesPress — https://yespress.io
Last updated: 2026-08-25